Imaging scans to predict immunotherapy response in liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with liver cancer that cannot be removed by surgery.
- You have received immunotherapy as part of your cancer treatment.
- You have had imaging scans (like CT or MRI) done before starting treatment.
- You have not had surgery to remove your liver cancer or a liver transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses artificial intelligence (AI) to analyze your CT or MRI scans and help predict how well immunotherapy might work for your liver cancer. The goal is to find better ways to match you with the right treatment and improve your outcomes.
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
This study uses advanced MRI scans and tumor samples to understand how the immune system behaves in liver cancer. It aims to improve personalized treatment by looking at the tumor's environment at different times.
This trial tests whether measuring the liver tumor with a CT scan can help doctors plan the best treatment. It aims to improve how well the treatment works and reduce side effects.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
This trial tests a new type of MRI scan (hyperpolarized 13C-MRI) in people with liver cancer who are already receiving radiation therapy, atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy). The goal is to see if the scan can help doctors better understand how the cancer responds to treatment.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.